Opexa Therapeutics (OPXA), a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology. Its leading therapy candidate includes Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. OPXA was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics in June 2006 < founded in 2003> and is based in The Woodlands, Texas.
December 26, 2013
Opexa (OPXA) closes 4.12 M offering at $1.70 for $8.054 M
December 23, 2013
Off to the holiday as a rally runs
December 20, 2013
One day’s “witching” does not make a trend
December 19, 2013
The element of uncertainty plagues investors
December 19, 2013
Opexa (OPXA) director sells while CFO buys shares
December 18, 2013
Once lionized, now rejected by those fickle investors
December 18, 2013
The trading finger is fickle
December 18, 2013
Futures edge to HIGHER open; RegMed reluctance buoyed by caution
December 18, 2013
Opexa (OPXA) Prices 4.12 M offering at $1.70
December 17, 2013
Uncertainty clouds the RegMed sector
35 companies, 1 interpreter!
Insight, foresight and recommendation
Opexa (OPXA) – OPXA’s P2b clinical trial of Tcelna® (imilecleucel-T) in secondary progressive multiple sclerosis (SPMS) (Abili-T trial) is nearing completion. Top line data is expected in early Q4/16. The final dose was administered to the last patient in 2/16 and approximately 98% of all patient visits have now been completed. The Abili-T clinical trial is being conducted at 35 clinical sites in the U.S. and Canada. Opexa has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Tcelna in SPMS. For Q1/16 OPXA reported a net loss of -$2.1 M, or -$0.31 per share, compared to a net loss of -$3.4 M or -$0.95 per share for Q1/15. RECOMMENDATION: BUY
buy
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.